west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "李艺贤" 2 results
  • The impact of primary tumor site on breast cancer prognosis post breast-conserving surgery

    ObjectiveThe aim of this study is to investigate the impact of primary tumor location on the prognosis of breast cancer patients undergoing breast-conserving surgery. MethodsPatient data were retrospectively collected from medical records of individuals who underwent breast-conserving surgery at the Affiliated Hospital of Southwest Medical University between January 2018 and December 2019. ResultsA total of 148 patients were included in this study. The distribution of tumors by location was as follows: the upper outer quadrant accounted for 52.0% (77/148), the lower outer quadrant for 14.2% (21/148), the upper inner quadrant for 14.9% (22/148), the lower inner quadrant for 12.1% (18/148), and the central region for 6.8% (10/148). No statistically significant differences were observed in the comparison of clinicopathological characteristics among breast cancer patients with tumors at different locations (P>0.05). The survival analysis revealed significant correlations between patient prognosis and tumor location, size, molecular classification, WHO grading, as well as endocrine and radiotherapy treatments. Patients with tumors located in the upper inner quadrant [HR=4.400, 95%CI(1.282, 15.099), P=0.019], lower inner quadrant [HR=4.400, 95%CI(1.282, 15.099), P=0.019], and central region [HR=5.238, 95%CI(1.174, 23.361), P=0.030] exhibited significantly higher risks of 5-year recurrence and metastasis compared to those with tumors in other locations. ConclusionsThis study indicates that primary tumor location in the inner quadrants and central region is associated with an increased risk of recurrence and metastasis in breast cancer patients following breast-conserving surgery, representing potential risk factors that warrant attention in clinical decision-making.

    Release date: Export PDF Favorites Scan
  • 曲妥珠单抗生物类似药与原研曲妥珠单抗联合帕妥珠单抗治疗HER2阳性乳腺癌患者疗效与安全性的回顾性队列研究

    目的比较HER2阳性乳腺癌患者在新辅助治疗中原研曲妥珠单抗与生物类似药的病理完全缓解(pathologic complete response,pCR)率及不良事件发生率的差异。方法采用回顾性分析法,收集 2021年1月至2022年10月期间在西南医科大学附属医院乳腺外科完成TCbHP方案新辅助治疗及手术治疗的 117例人类表皮生长因子受体2(human epidermal growth factor receptor 2,HER2) 阳性乳腺癌患者的临床病理资料。疗效评价依据实体肿瘤疗效评价标准(RECIST)1.1和 Miller-Payne(MP)系统,采用不良事件通用术语标准5.0进行不良事件发生率统计。结果117例患者中达到总体病理完全缓解(total pathologic complete response,tpCR)者曲妥珠单抗生物类似药汉曲优(HLX02,Zercepac)组占比70.2% (33/47),原研曲妥珠单抗赫赛汀组占比72.9% (51/70),2组比较差异无统计学意义(P=0.755);达到乳腺病理完全缓解(breast pathologic complete response,bpCR)者汉曲优组占比76.6% (36/47),赫赛汀组占比74.3.9% (52/70),2组比较差异无统计学意义(P=0.777)。分子分型为HER2+HR+ (三阳性)组与HER2+HR–(HER2过表达)组患者的tpCR率比较差异有统计学意义(61.6%比88.6%,P=0.002),bpCR率比较差异也有统计学意义(67.1%比88.6%,P=0.009)。在HER2+HR+患者中汉曲优组与赫赛汀组的tpCR率比较差异无统计学意义(66.7%比57.5%,P=0.423),bpCR率比较差异也无统计学意义(75.8%比60.0%,P=0.154);在HER2+HR–患者中汉曲优组与赫赛汀组的的tpCR率比较差异无统计学意义(78.6%比93.3%,P=0.354),bpCR率比较差异也无统计学意义(78.6%比93.3%,P=0.354)。治疗后所有患者均出现了可控的不良事件, 2组患者在心脏、血液系统和肝肾功能方面的不良事件发生率以及 ≥3 级不良事件的发生率均相似,差异均无统计学意义(P>0.05)。结论赫赛汀与其生物类似药汉曲优在新辅助治疗中的疗效和安全性相似,这为 HER2 阳性乳腺癌患者提供了更多的治疗选择。

    Release date:2024-04-25 01:50 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content